ESCAPE Trial

The ESCAPE trial demonstrates the benefits of endovascular treatment compared to conventional treatment for patients with acute ischemic stroke.  The patients that were recruited for this study had small infarct core (based on ASPECTS), proximal intracranial occlusion, and the presence of collaterals.  The study also ensured that the patients could be treated fast: a target CT to groin puncture of 60 minutes and a target CT to reperfusion of 90 minutes.  Furthermore, the study focused on safe and high reperfusion rates.

There were 22 sites from North America, Europe, UK and Asia that recruited patients in ESCAPE.  There were 316 patients recruited before the trial was stopped by the DSMB for efficacy.